Stockreport

Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant to Treat Patients with Cushing’s Syndrome

Corcept Therapeutics Incorporated  (CORT) 
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corcept.com/investors
PDF MENLO PARK, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commerciali [Read more]